Eli Lilly and Company
Explore Eli Lilly and
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
3 leaders · Full leadership timeline
Lilly has transformed from a broad pharmaceutical company into one of the world's most valuable drugmakers because of its cardiometabolic portfolio and pipeline. The core question is how long demand, capacity, and patent protection can compound.
Eli Lilly's business model is characterized by substantial, high-risk R&D bets with binary outcomes. The company funds its extensive pipeline through the lucrative sales of specialized treatments in diabetes, oncology, and immunology. Its current astronomical valuation is entirely dependent on maintaining its duopoly with Novo Nordisk in the GLP-1 (weight loss and diabetes) drug market.
Chair, President, and Chief Executive Officer
Leads Lilly through the obesity, diabetes, manufacturing-capacity, and pipeline expansion era.
Former Chairman and Chief Executive Officer
Led Lilly through a global pharmaceutical expansion period and major product-cycle challenges.
Founder
Established the company's manufacturing and quality-control culture.
Novo Nordisk's strengths are real and should not be underestimated: the company has manufactured insulin and diabetes drugs since 1923 (the same year Lilly first commercialized insulin in North America), its manufacturing capabilities have historically been more developed in the GLP-1 space, and Wegovy's clinical cardiovascular outcomes data from the SELECT trial — showing a 20 percent reduction in major cardiovascular events in patients with obesity and established cardiovascular disease — represents a landmark label claim that Lilly sought to match or exceed with tirzepatide's own cardiovascular outcomes program, the SURPASS-CVOT study, which also demonstrated significant cardiovascular risk reduction. Patent protection and the threat of generic and biosimilar competition represent structural long-term risks to Lilly's revenue model. While Lilly challenged the constitutionality of the program in federal court — a lawsuit that courts have largely not sustained — the company has also engaged constructively with the negotiation process, recognizing that Medicare market access is too important to sacrifice. Clinical development risk remains inherent to the pharmaceutical business model. The company's Alzheimer's program illustrates this risk: after decades of failures in the space, donanemab received approval, but real-world uptake of Alzheimer's amyloid therapies has been slower than many analysts anticipated, constrained by the complexity of patient identification via amyloid PET imaging or cerebrospinal fluid testing, infusion center capacity, and reimbursement coverage decisions. Lilly threw its full manufacturing and scientific resources at the insulin problem.
David A. Ricks has been the highly successful CEO since 2017. He is a 'Lilly Lifer', having started at the company in 1996 and slowly aggressively working his way up to the absolute top.
He took massive risks. When he became CEO, the company was struggling with massive patent expirations. Instead of aggressively buying other companies, Ricks doubled down on internal R&D, heavily funding the highly risky Alzheimer's and obesity pipelines that ultimately exploded into massive success.
John Lechleiter was the CEO from 2008 to 2016. He was a highly brilliant PhD chemist who managed the company through the absolute catastrophic 'Patent Cliff' (when Zyprexa and Cymbalta lost exclusivity). His massive focus on scientific integrity kept the pipeline alive for Ricks to eventually harvest.
Yes, for a very long time. The founder's son (Josiah) and grandson (Eli Jr.) successfully ran the massive company until 1953. Eli Lilly Jr. was an absolute visionary who transitioned the company from a chaotic chemical factory into a highly rigid, massive modern scientific corporation.
Manufacturing logistics. His massive R&D bet worked, but now he is under incredibly intense pressure from doctors and Wall Street to fix the catastrophic global shortages of Mounjaro and Zepbound. If he cannot manufacture it fast enough, Novo Nordisk will steal the patients.